abbott mix busi add narrow econom
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
abbott expand medic devic footprint addit
st jude medic continu improv profit
segment nutrit devic diagnost establish
pharmaceut although abbott made progress last
six year still lag key rival profit measur despit
compet busi character attract
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott new freestyl libr blood glucos
monitor offer compel innov anticip abbott
substanti footprint latin america russia establish
pharmaceut product also deliv steadi growth
also applaud sale abbott epp busi develop
market optic unit reshuffl put abbott
favor posit focu faster grow market
brand gener emerg market addit st jude
heart-focus portfolio along smaller tuck-in significantli
broaden abbott cardiac devic product offer rais
firm abil compet hospit client seek winnow
still forecast mid-single-digit revenu growth abbott
think potenti firm goos growth key
product line meantim see opportun
abbott enhanc effici fuel earn growth address
situat
larg
manag control abbott exceed expect
close profit gap competit set upsid
valuat
low-hang fruit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net incom averag number common
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
stent cathet infant formula nutrit liquid adult molecular
point-of-car diagnost equip abbott deriv approxim
sale outsid unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rais fair valu estim per share
reflect cash flow realiz sinc last updat
continu expect top-lin strength domest
launch freestyl libr on-going adopt alin
system comprehens test panel return
growth infant formula market china new
regulatori hurdl process obtain infant formula
clearanc china somewhat pain addit
regul reduc number competitor
expect benefit abbott maintain
optimist expect growth electrophysiolog
neuromodul product thank new
product launch underli growth demand
fuel structur heart intern
nutrit freestyl libr point-of-car diagnost
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv firm
leverag distribut infrastructur built
penetr emerg market across product
segment extract cost synergi recent
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth molecular diagnost
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag annual follow
addit st jude aler howev assum
declin stent sale
offer superior technolog long haul mute
perform mitraclip portico transcathet
nutrit
low-single-digit growth diagnost assum abbott
rais gross margin basi point
think addit st jude push abbott toward
wider side narrow moat fulli convinc
abbott tip wide moat categori
especi firm nurtur kind on-going
occasion revolutionari innov necessari
secur reimburs longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent immunoassay
market abbott particip ration oligopoli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gener oper like consum busi
gener mainli sold less develop market
often lack well-develop infrastructur distribut
instead abbott must sell product directli pharmaci
chain physician result brand recognit
reput key factor abbott leverag sell
fragment market also translat less price
pressur abbott could chang longer term
emerg market turn tender system
character develop nation howev chang
remain
near medium term think abbott benefit
addit st jude impress expertis
cardiac rhythm manag structur heart heart
failur howev juri still abbott abil
nurtur renew innov area long haul
thu far abbott done credibl job commerci
alreadi st jude pipelin less
confid abbott gener greater
leap
track record earlier
innov base
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
enjoy benefit intang asset
think nutrit busi one moatiest
part new abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment sold
outsid busi frequent call brand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend anticip strength cardiac devic segment
divis diabet busi off-set
current weak neuromodul molecular
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oaggress cost-cut plan propel abbott
bottom-lin growth quickli top-lin growth
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
upstart like
oslow growth fall birth rate china offer
abbott nutrit
segment could damp nutrit firm
final overcam regulatori chang china
drag growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
medium term issu debt share financ
purchas sale vision-car busi
purchas st jude abbott debt/ebitda hover around
time end two year
manag brought debt level closer time
end expect debt/ebitda fall
time remain comfort abbott
estim interest coverag ebitda/interest time
coverag rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov competitor
particularli issu medic devic
diagnost busi despit abbott recent effort
better insul recal like infant formula
recal china risk product qualiti issu
recal remain damag firm brand
relationship medic profession hospit
custom payer tighten purs string abbott could
see greater price pressur furthermor hospit
cardiac therapeut area abbott could find
disadvantag compar key rival
johnson johnson final abbott oper
scrutini food drug administr
well regulatori agenc oversea lead
delay product approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
new york mellon corp
fidel manag research compani
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit piram st jude
medic remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white took helm ceo chairman
board follow year tenur abbott date
back provid experi need handl
compani mani oper line find somewhat
worrisom white allow non-abbvie-rel
busi becom flabbi watch white
made progress profit front past
sever year still plenti room
improv abbott catch key
competitor board heavili weight
toward independ former execut
publicli trade firm chicago area particularli
pleas see stark former ceo st jude join
board expect experi lead st jude ramp
innov could posit influenc abbott
said think room improv
compens polici -- move away benchmark
involv adjust earn per share ebit
measur focus return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chang fve jan
finish fourth quarter full year close
expect top bottom line
leav fair valu estim unchang although growth
nutrit seem moder recoveri seen
chines infant formula market adopt new
product includ alin diagnost instrument
penetr freestyl libr continu glucos monitor
new product indic cardiac area drove
fourth-quart organ revenu solid
see littl chang think abbott narrow
econom moat point
remain optimist abbott diabet busi
thank european launch next-gen libr
featur alarm signal low high blood glucos level
real time well medicar decis cover
origin libr user-friendli libr
price set product apart competitor also
favor new destin therapi indic
heartmat left ventricular assist devic patient
advanc heart failur lvad origin
indic short-term use wait heart
transplant long-term destin therapi attract
opportun roughli patient
need transplant sever thousand get one
remain patient could benefit lvad therapi
hand abbott saw soft domest
fourth-quart cardiac rhythm manag busi
declin year year recogn abbott
especi strong fourth-quart perform prior-
year period launch mri-compat devic
howev think firm disadvantag
curiou see abbott pipelin compet
directli boston scientif
front
abbott manag chalk weak
 unit relat larger market growth
entir convinc boston seen
strong adopt s-icd leadless pacemak
respect weve discuss suspect
medtron effort sign hospit risk-
base contract tyrx antibacteri envelop
tradit devic could affect tradit
competit dynam market better
sens market boston report
next month meantim detail medtron
novel approach chang payment model
strategi help enhanc medtron
value-bas payment reinforc wide moat
abbott see decent result thank nutrit
diagnost freestyl libr oct
abbott report third-quart result held
surpris remain track hit full-year
project top bottom line weve made
materi chang forecast plan rais
fair valu estim modestli reflect cash flow realiz
sinc last updat overal think narrow-moat abbott
execut well new product cycl
meaning innov particular adopt alin
diagnost strength electrophysiolog portfolio
ablat irrig cathet newli approv
freestyl libr sensor last day long-term
concern abbott abil nurtur cultur
innov remain mind
pleas see intern pediatr nutrit
return double-digit organ growth nice
return patienc investor display wait
china work new regulatori framework infant
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
formula last year one largest
multi-national competitor chines market abbott
resourc compli new govern regul
caus smaller nativ formula produc
leav market
continu success freestyl libr flash also
high point abbott set libr price significantli
lower dexcom medtron guardian cgm
system abbott abl take share
suspect draw type patient away multipl
finger stick day addit weve seen
monitor technolog abbott sensor offer
accuraci earlier sensor expect abbott
maintain pressur user-friendli
price libr rais bar
come recent transcathet cardiovascular
therapeut confer surpris coapt
trial result demonstr efficaci mitraclip
patient sever function mitral regurgit
artifact underli heart failur enlarg left
ventricl prospect expand mitraclip
indic beyond degen mitral regurgit
significantli larger pool fmr patient
attract remain somewhat cautiou sever
reason first favor coapt data inconsist
earlier mitra-fr data fail demonstr
benefit month exampl patient outcom
rehospit mortal differ
trial term patient select practition
experi time frame make difficult compar
result nonetheless conflict trial data suggest well
need build studi consensu reach
second clear durabl coapt result
underli heart failur continu progress even
slower rate would seen without mitraclip
pull mitral valv askew three four year
despit current success still hold
question abbott abil consist innov
especi medic devic on-going cultiv
necessari maintain price power
addit seen competitor
move aggress chang basi
competit technolog innov
price entri weve pay particular attent
abbott cardiac rhythm manag segment sinc
launch mri-compat pacemak implant
cardiovert defibril last fall base
histor cycl new product launch would
expect see abbott outpac market growth captur
anywher point market share first
see abbott busi pop year-
over-year growth fourth quarter immedi
follow food drug administr approv
product septemb howev energi
dissip three quarter mute result
follow three quarter
manag sign roughli hospit base onto
risk-bas contract featur antibacteri
tyrx envelop contract cover
cost patient whose devic becom infect
implant tyrx
system surmis proposit take
financi risk costli infect mileston
reach critic mass hospit contract
shield firm full brunt abbott new product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
